# Evaluating Treatment Resistant Dermatitis TaroIIR

> **NCT03050294** · PHASE4 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 24 (actual)

## Conditions studied

- Atopic Dermatitis
- Psoriasis

## Interventions

- **BEHAVIORAL:** Phone calls
- **DRUG:** Desoximetasone 0.25% spray

## Key facts

- **NCT ID:** NCT03050294
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-01
- **Primary completion:** 2017-06-01
- **Final completion:** 2017-06-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03050294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03050294, "Evaluating Treatment Resistant Dermatitis TaroIIR". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03050294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*